drugset
drugset / Trial / NCT04970043

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

NCT04970043 ↗

Unknown 58 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients

Timeline

Start
2021-07-31
Primary completion
2024-07-30
Completion
2024-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Carboplatin Small molecule — —
Subject Pemetrexed Small molecule 500 mg/m2 —

Indications

lung carcinoma